Q1 Earnings Estimate for biote Issued By B. Riley

biote Corp. (NASDAQ:BTMD) – B. Riley issued their Q1 2025 earnings estimates for shares of biote in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst J. Van. Sinderen forecasts that the company will post earnings per share of $0.04 for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q2 2025 earnings at $0.05 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.42 EPS and FY2027 earnings at $0.71 EPS.

Separately, Craig Hallum decreased their price objective on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.

biote Price Performance

Shares of biote stock opened at $4.07 on Monday. The company’s fifty day simple moving average is $4.88 and its 200-day simple moving average is $5.51. The stock has a market capitalization of $221.15 million, a PE ratio of 15.65 and a beta of 1.07. biote has a 1-year low of $3.04 and a 1-year high of $8.44.

Insider Activity at biote

In other news, major shareholder Guines Llc bought 750,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were bought at an average price of $3.22 per share, for a total transaction of $2,415,000.00. Following the purchase, the insider now owns 3,820,938 shares in the company, valued at $12,303,420.36. This represents a 24.42 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Stephen Mark Cone bought 38,104 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $3.88 per share, for a total transaction of $147,843.52. Following the purchase, the director now owns 160,829 shares in the company, valued at $624,016.52. This represents a 31.05 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 788,204 shares of company stock worth $2,563,218. 13.90% of the stock is owned by corporate insiders.

Institutional Trading of biote

Hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD purchased a new stake in biote in the 4th quarter worth $67,000. Commonwealth Equity Services LLC purchased a new stake in biote in the 4th quarter worth $68,000. Public Employees Retirement System of Ohio purchased a new stake in biote in the 4th quarter worth $69,000. Intech Investment Management LLC purchased a new stake in biote in the 4th quarter worth $71,000. Finally, SG Americas Securities LLC purchased a new stake in biote in the 4th quarter worth $76,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.